33 results
10-K
2023 FY
EX-31.2
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
is responsible for inhibitory neurotransmission in the brain. Alterations in GABAergic signaling have been associated with mood disorders.
BDNF Release … the filing, prosecution, maintenance, and management of the licensed patent rights, provided that we will be responsible for the cost of prosecuting
10-K
2023 FY
EX-31.1
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
UPLOAD
2233zhv2hho
22 Dec 23
Letter from SEC
12:00am
8-K
EX-10.1
1oxk0 tuyy6gatdtsxp9
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
10-Q
EX-31.2
7ojf y9ywi1lw2y728
15 Sep 23
Quarterly report
4:45pm
10-Q
EX-31.1
q2p9jki3 27t6m
15 Sep 23
Quarterly report
4:45pm
424B4
sfqejrdrsun1ha in
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
lzn4vwe6nbj59aa
4 Aug 23
Prospectus with pricing info
12:59pm